The phenotypic variability of amyotrophic lateral sclerosis

Nature Reviews Neurology

Volumn 10, Issue 11, 2014, Pages 661-670

  Swinnen, Bart ^a   Robberecht, Wim ^a  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; EPHRIN RECEPTOR A4;

AMYOTROPHIC LATERAL SCLEROSIS; CEREBELLAR ATAXIA; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DROPPED HEAD SYNDROME; EPHA4 GENE; EXTRAPYRAMIDAL SYNDROME; FLAIL ARM SYNDROME; FLAIL LEG SYNDROME; FRONTOTEMPORAL DEMENTIA; GENE; HUMAN; MOLECULAR PATHOLOGY; MOTONEURON; MUSCLE ATROPHY; ONSET AGE; OPHTHALMOPLEGIA; OUTCOME ASSESSMENT; PHENOTYPE; REVIEW; SOD1 GENE; SYNDROME; TMEM106B GENE; UNC13A GENE; VIGNETTE; COMPLICATION; GENETICS; PATHOPHYSIOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE PROGRESSION; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; PHENOTYPE;

EID: 84908481936     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.184     Document Type: Review

References (110)

1. Renton, A. E., Chiò, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17-23 (2014).
2. Robberecht, W. & Philips, T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248-264 (2013).
3. Amato, A. & Russell, J. Neuromuscular Disorders 97-113 (McGraw-Hill, 2008).
4. Rowland, L. P. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688-1700 (2001).
5. Ravits, J. M. & La Spada, A. R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805-811 (2009).
6. Chiò, A., Calvo, A., Moglia, C., Mazzini, L. & Mora, G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosurg. Psychiatry 82, 740-746 (2011).
7. Duchenne De Boulogne, G. Paralysie musculaire progressive de la langue, du voile du palais et des levres [French]. Arch. Gen. Med. 2, 283-296 (1860).
8. Pinto, S., Pinto, A. & De Carvalho, M. Do bulbar-onset amyotrophic lateral sclerosis patients have an earlier respiratory involvement than spinal-onset amyotrophic lateral sclerosis patients? Eura Medicophys. 43, 505-509 (2007).
9. Turner, M. R. et al. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J. Neurol. Sci. 294, 81-85 (2010).
10. Shoesmith, C. L., Findlater, K., Rowe, A. & Strong, M. J. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J. Neurol. Neurosurg. Psychiatry 78, 629-631 (2007).
11. Al-Chalabi, A. & Hardiman, O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 9, 617-628 (2013).
12. Sabatelli, M., Conte, A. & Zollino, M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin. Genet. 83, 408-416 (2013).
13. Al-Chalabi, A. & Lewis, C. M. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum. Hered. 71, 281-288 (2011).
14. Andersen, P. M. & Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 7, 603-615 (2011).
15. Sabatelli, M. et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology 71, 876-881 (2008).
16. Pupillo, E., Messina, P., Logroscino, G. & Beghi, E. Long-term survival of amyotrophic lateral sclerosis: a population-based study. Ann. Neurol. 75, 287-297 (2014).
17. Belzil, V. V. et al. Novel FUS deletion in a patient with juvenile amyotrophic lateral sclerosis. Arch. Neurol. 69, 653-656 (2012).
18. Yamashita, S. et al. Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. J. Neurol. 259, 1039-1044 (2012).
19. Bäumer, D. et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 75, 611-618 (2010).
20. Dierick, I. et al. Relative contribution of mutations in genes for autosomal dominant distal hereditary motor neuropathies: a genotype-phenotype correlation study. Brain 131, 1217-1227 (2008).
21. Chen, Y.-Z. et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74, 1128-1135 (2004).
22. Forbes, R. B., Colville, S. & Swingler, R. J. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing 33, 131-134 (2004).
23. Zoccolella, S. et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J. Neurol. Neurosurg. Psychiatry 79, 33-37 (2008).
24. Iwanaga, K. et al. Neuropathology of sporadic amyotrophic lateral sclerosis of long duration. J. Neurol. Sci. 146, 139-143 (1997).
25. Byrne, S. et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 11, 232-240 (2012).
26. Chiò, A. et al. Extensive genetics of ALS: a population-based study in Italy. Neurology 79, 1983-1989 (2012).
27. Van Rheenen, W. et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology 79, 878-882 (2012).
28. Van Blitterswijk, M. et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 12, 978-988 (2013).
29. Régal, L. et al. The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis. Arch. Neurol. 63, 262-267 (2006).
30. Penco, S. et al. Phenotypic heterogeneity in a SOD1 G93D Italian ALS family: an example of human model to study a complex disease. J. Mol. Neurosci. 44, 25-30 (2011).
31. Kim, W. et al. Anticipation and phenotypic heterogeneity in Korean familial amyotrophic lateral sclerosis with superoxide dismutase 1 gene mutation. J. Clin. Neurol. 3, 38-44 (2007).
32. Brooks, B. R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. Sci. 124, 96-107 (1994).
33. Rowland, L. P. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve 41, 161-165 (2010).
34. Cudkowicz, M., McKenna-Yasek, D., Chen, C., Hedley-Whyte, E. & Brown, R. J. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann. Neurol. 43, 703-710 (1998).
35. Cervenakova, L., Protas, I. & Hirano, A. Progressive muscular atrophy variant of familial amyotrophic lateral sclerosis (PMA/ALS). J. Neurol. Sci. 177, 124-130 (2000).
36. Van der Graaff, M. M. et al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain 134, 1211-1228 (2011).
37. Prudlo, J. et al. White matter pathology in ALS and lower motor neuron ALS variants: a diffusion tensor imaging study using tract-based spatial statistics. J. Neurol. 259, 1848-1859 (2012).
38. Ince, P. G. et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 60, 1252-1258 (2003).
39. Gamez, J., Cervera, C. & Codina, A. Flail arm syndrome or Vulpian-Bernhart's form of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 67, 258 (1999).
40. Hu, M., Ellis, C., Al-Chalabi, A., Leigh, P. & Shaw, C. Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J. Neurol Neurosurg. Psychiatry 65, 950-951 (1998).
41. Wijesekera, L. C. et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 72, 1087-1094 (2009).
42. Kobayashi, Z. et al. Pseudopolyneuritic form of ALS revisited: clinical and pathological heterogeneity. Neuropathology 30, 372-380 (2010).
43. Gourie-Devi, M., Nalini, A. & Sandhya, S. Early or late appearance of "dropped head syndrome" in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 74, 683-687 (2003).
44. Gordon, P. H. et al. The natural history of primary lateral sclerosis. Neurology 66, 647-653 (2006).
45. Le Forestier, N. et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 124, 1989-1999 (2001).
46. D'amico, E., Pasmantier, M. & Lee, Y.-W. Clinical evolution of pure upper motor neuron disease/ dysfunction (PUMND). Muscle Nerve 47, 28-32 (2013).
47. Gordon, P., Cheng, B. & Katz, I. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology 72, 1947-1953 (2009).
48. Rajabally, Y. A., Hbahbih, M. & Abbott, R. J. Hemiplegic ALS: Mills syndrome. Neurology 64, 1984-1985 (2005).
49. Gastaut, J.-L. & Bartolomei, F. Mills' syndrome: ascending (or descending) progressive hemiplegia: a hemiplegic form of primary lateral sclerosis? J. Neurol. Neurosurg. Psychiatry 57, 1280-1281 (1994).
50. Kim, W.-K. et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 73, 1686-1692 (2009).
51. Van den Berg-Vos, R. M. et al. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes. Arch. Neurol. 66, 751-757 (2009).
52. Strong, M. J. & Yang, W. The frontotemporal syndromes of ALS. Clinicopathological correlates. J. Mol. Neurosci. 45, 648-655 (2011).
53. Phukan, J., Pender, N. P. & Hardiman, O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 6, 994-1003 (2007).
54. Lillo, P. & Hodges, J. R. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J. Clin. Neurosci. 16, 1131-1135 (2009).
55. Mioshi, E. et al. Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology 82, 149-155 (2014).
56. Rippon, G. A. et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch. Neurol. 63, 345-352 (2006).
57. Ferrari, R., Kapogiannis, D., Huey, E. D. & Momeni, P. FTD and ALS: a tale of two diseases. Curr. Alzheimer Res. 8, 273-294 (2011).
58. Olney, R. K. et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 65, 1774-1777 (2005).
59. Achi, E. Y & Rudnicki, S. A. ALS and frontotemporal dysfunction: a review. Neurol. Res. Int. 2012, 806306 (2012).
60. Neumann, M. et al. Ubiquitinated TDP-43 n frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133 (2006).
61. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245-256 (2011).
62. Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268 (2011).
63. Gijselinck, I. et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 11, 54-65 (2012).
64. Cooper-Knock, J., Shaw, P. J. & Kirby, J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 127, 333-345 (2014).
65. Snowden, J. S. et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135, 693-708 (2012).
66. Cudkowicz, M. et al. Epidemiology of mutations n superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 41, 210-221 (1997).
67. Millecamps, S. et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J. Med. Genet 49, 258-263 (2012).
68. Hodges, J. Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. Brain 135, 652-655 (2012).
69. Bieniek, K. F. et al. Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia. JAMA Neurol. 71, 775-781 (2014).
70. Lindquist, S. G. et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin. Genet. 83, 279-283 (2013).
71. Hensman Moss, D. J. et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82, 292-299 (2014).
72. Watts, G. D. et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377-381 (2004).
73. Kim, D. H. J. et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467-473 (2013).
74. Atsuta, N. et al. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 276, 163-169 (2009).
75. Steele, J. C. & McGeer, P. L. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 70, 1984-1990 (2008).
76. Kaji, R., Izumi, Y., Adachi, Y. & Kuzuhara, S. ALS-parkinsonism-dementia complex of Kii and other related diseases in Japan. Parkinsonism Relat. Disord. 18 (Suppl. 1), S190-S191 (2012).
77. Gilbert, R. M. W., Fahn, S., Mitsumoto, H. & Rowland, L. P. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov. Disord. 25, 1868-1875 (2010).
78. Manno, C., Lipari, A., Bono, V., Taiello, A. C. & La Bella, V. Sporadic Parkinson disease and amyotrophic lateral sclerosis complex (Brait-Fahn-Schwartz disease). J. Neurol. Sci. 326, 104-106 (2013).
79. Pinkhardt, E. H., Sperfeld, A.-D., Gdynia, H.-J., Ludolph, A. C. & Kassubek, J. The combination of dopa-responsive parkinsonian syndrome and motor neuron disease. Neurodegener. Dis. 6, 95-101 (2009).
80. Annesi, G. et al. DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Ann. Neurol. 58, 803-807 (2005).
81. Desai, J. & Swash, M. Extrapyramidal involvement in amyotrophic lateral sclerosis: backward falls and retropulsion. J. Neurol. Neurosurg. Psychiatry 67, 214-216 (1999).
82. Park, H. K. et al. Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism. J. Neurol. Sci. 301, 12-13 (2011).
83. Frolov, A. et al. C9ORF72 expansions, parkinsonism, and parkinson disease. Neurology 81, 808-811 (2013).
84. Pradat, P.-F. Association of chorea and motor neuron disease. Mov. Disord. 17, 402-423 (2002).
85. Gamez, J. et al. Chorea-ballism associated with familial amyotrophic lateral sclerosis. A clinical, genetic, and neuropathological study. Mov. Disord. 23, 434-438 (2008).
86. Tada, M. et al. Coexistence of Huntington's disease and amyotrophic lateral sclerosis: a clinicopathologic study. Acta Neuropathol. 124, 749-760 (2012).
87. Sadeghian, H., O'Suilleabhain, P. E., Battiste, J., Elliott, J. L. & Trivedi, J. R. Huntington chorea presenting with motor neuron disease. Arch. Neurol. 68, 650-652 (2011).
88. Nanetti, L. et al. Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. J. Neurol. 256, 1926-1928 (2009).
89. Elden, A. C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075 (2011).
90. Ross, O. A. et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 20, 3207-3212 (2011).
91. Van Damme, P. et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 76, 2066-2072 (2011).
92. Isaacs, J. D. et al. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J. Neurol. Neurosurg. Psychiatry 78, 750-753 (2007).
93. Shibata, N. et al. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol. 55, 481-490 (1996).
94. Andersen, P. M. et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat. Genet. 55, 61-66 (1995).
95. Lee, H. L. & Lee, J. K. Amyotrophic lateral sclerosis with an acute hypertensive crises. Ann. Rehabil. Med. 36, 418-422 (2012).
96. Baltadzhieva, R., Gurevich, T. & Korczyn, A. D. Autonomic impairment in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 18, 487-493 (2005).
97. Merico, A. & Cavinato, M. Autonomic dysfunction in the early stage of ALS with bulbar involvement. Amyotroph. Lateral Scler. 12, 363-367 (2011).
98. Zhai, P., Pagan, F., Statland, J., Butman, J. A. & Floeter, M. K. Primary lateral sclerosis: a heterogeneous disorder composed of different subtypes? Neurology 60, 1258-1265 (2003).
99. Green, P. et al. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in C20ORF54. Am. J. Hum. Genet. 86, 485-489 (2010).
100. Abrahams, S. et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 119, 2105-2120 (1996).
101. Chervyakov, A. V. et al. Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis. Muscle Nerve 9, 408-419 (2014).
102. Pun, S., Santos, A. F., Saxena, S., Xu, L. & Caroni, P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 9, 408-419 (2006).
103. Frey, D. et al. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J. Neurosci. 20, 2534-2542 (2000).
104. Vanselow, B. K. & Keller, B. U. Calcium dynamics and buffering in oculomotor neurones from mouse that are particularly resistant during amyotrophic lateral sclerosis (ALS)-related motoneurone disease. J. Physiol. 525, 433-445 (2000).
105. Kaplan, A. et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron 81, 333-348 (2014).
106. Van Hoecke, A. et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 18, 1418-1422 (2012).
107. Saxena, S. et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron 80, 80-96 (2013).
108. Van Den Bosch, L., Van Damme, P., Bogaert, E. & Robberecht, W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1068-1082 (2006).
109. Diekstra, F. P. et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging 33, 630.e3-630.e8 (2012).
110. Vass, R., Hu, W. T. & Grossman, M. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 121, 373-380 (2011).